Loading
1I
111, Inc. Stock: price and insider trades · United States
111, Inc.: what insiders have been doing
111, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 51 filings signed by 4 insiders.
No insider bought on the market over the period, while 2 insiders filed 20 sales totalling €55k. The amount is not disclosed for 11 filings. Sun Jian David filed the largest sale, €15k, on 29 May 2026, which represents 0.067% of the company's market value.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 51 filings, this issuer sits above that mark. Looking back to 2026, when coverage begins, insiders filed no purchases and 20 sales. In its latest annual report filed with the SEC (20-F, fiscal year ended 31 December 2025), the company reported revenue of 12.56 bn CNY and net income of -22.5 m CNY.
Typically, a trade is published a median of 31 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
53
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€55,315
20 ops. · all time
Who traded when
BuySaleJian David Sun17 sales
Yang Luke Chen17 sales
Jun Justin Luo2 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,715 of 24,148 companies
32.7
score / 100
Value54
Quality12
FCF yld·
Earn yld·
EV/EBITDA10.6x
ROE-28%
Gross mgn5.8%
Net mgn-0.5%
Debt/EBITDA9.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.09
Analyst consensus
Income statement
RevenueUS$12.6B
Gross profitUS$723.4M6% margin
EBITDAUS$24.9M0% margin
Net income-US$66.4M-1.0% margin
Valuation
PER (trailing)0.3x
Beta0.67
Balance sheet & cash
Market capUS$27.2M
Total debtUS$236.7M
Free Cash FlowUS$114.7M
Debt / Equity177%
Profitability & ownership
ROE-27.5%
ROA-1.3%
% insiders28.6%
% institutions0.7%
Last declaration on 29 September 2026
Declarations53 total
126,295 shares0RSUs (Class A)SEC:0001104659-26-111575:0
54,759 shares0RSUs (Class A)SEC:0001104659-26-111575:1
413,168 shares0RSUs (Class A)SEC:0001104659-26-111575:2
38,120 shares@ US$0.180.022% mcap18.0% of flowRSUs (Class A)SEC:0001104659-26-111575:8
54,759 shares0RSUs (Class A)SEC:0001104659-26-110132:1
126,295 shares0RSUs (Class A)SEC:0001104659-26-110132:0
413,168 shares0RSUs (Class A)SEC:0001104659-26-110132:2
3,400 shares@ US$0.252.7% of flowRSUs (Class A)SEC:0001104659-26-110132:4
49,920 shares@ US$0.2336.2% of flowRSUs (Class A)SEC:0001104659-26-110132:5
44,000 shares@ US$0.2331.9% of flowRSUs (Class A)SEC:0001104659-26-110132:6
44,000 shares@ US$0.180.025% mcap25.3% of flowRSUs (Class A)SEC:0001104659-26-110132:7
413,168 shares0RSUs (Class A)SEC:0001104659-26-074262:2
378,737 shares0RSUs (Class A)SEC:0001104659-26-074262:1
54,759 shares0RSUs (Class A)SEC:0001104659-26-074263:1
413,168 shares0RSUs (Class A)SEC:0001104659-26-074263:2
12,000 sharesRSUs (Class A)SEC:0001104659-26-074262:5
115,440 sharesRSUs (Class A)SEC:0001104659-26-074262:6
111,100 sharesRSUs (Class A)SEC:0001104659-26-074262:7
58,800 sharesRSUs (Class A)SEC:0001104659-26-074262:8
49,920 sharesRSUs (Class A)SEC:0001104659-26-074263:5
44,000 sharesRSUs (Class A)SEC:0001104659-26-074263:6
18,366 shares0RSUs (Class A)SEC:0001104659-26-074262:0
126,295 shares0RSUs (Class A)SEC:0001104659-26-074263:0
12,000 sharesRSUs (Class A)SEC:0001104659-26-073118:5
115,440 sharesRSUs (Class A)SEC:0001104659-26-073118:6
25 of 53 declarations
About 111, Inc.
111, Inc. (ticker: YI) is a U.S.-listed company traded on the NASDAQ, but its operating footprint is predominantly in mainland China. According to its latest SEC filings, the company’s business address is in Shanghai, and the group continues to describe itself as a tech-enabled healthcare platform focused on digitally empowering the upstream and downstream segments of China’s pharmaceutical industry. For international investors, that combination matters: the listing is in the United States, while the operating model, regulatory exposure and end-market dynamics are largely Chinese. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738906/000110465926052002/yi-20251231x20f.htm?utm_source=openai))
111, Inc. was built around the idea of connecting participants across the healthcare and pharmaceutical value chain. Rather than operating as a traditional drugmaker, it positions itself as a platform business spanning pharmaceutical distribution, digital commerce, supply-chain enablement and related healthcare services. Its filings describe a business that historically operated through its PRC subsidiary and contractual arrangements in China, reflecting the structure commonly used by China-based companies accessing U.S. capital markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738906/000110465926052002/yi-20251231x20f.htm?utm_source=openai))
Read moreShow less
The company’s core business lines are centered on pharmaceutical distribution and technology-enabled services. In practical terms, that means facilitating transactions between suppliers, pharmacies and healthcare channels, while also providing digital tools and operational infrastructure that help improve ordering, fulfillment and commercial efficiency. 111, Inc. has also emphasized a strategic shift toward an asset-light model, suggesting an effort to reduce capital intensity and streamline operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738906/000095010325016208/dp238799_ex9901.htm?utm_source=openai))
From a competitive standpoint, 111 operates in a large but crowded Chinese healthcare and pharma distribution ecosystem. Its value proposition rests on platform integration, digital workflow capabilities, supply-chain execution and its ability to serve both upstream and downstream participants. In this type of market, scale alone is not enough; execution quality, regulatory compliance, logistics reliability and data capabilities are key differentiators. The company also highlights meaningful regulatory and operating risks tied to its China base, including policy uncertainty, data/privacy compliance and the constraints facing offshore-listed China companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738906/000110465926052002/yi-20251231x20f.htm?utm_source=openai))
Recent developments point to an ongoing restructuring process. In its 2025 Form 20-F, 111, Inc. disclosed a strategic structural optimization plan in the third quarter of 2025, including the divestiture of 100% interests in three subsidiaries to independent third-party investors. The company has also continued to frame its communications around business transformation and operating improvement. For investors, YI should be viewed as a specialized NASDAQ healthcare-platform story with meaningful execution potential, but also with elevated regulatory and jurisdictional risk tied to China. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738906/000110465926052002/yi-20251231x20f.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
